Development of a clinical risk scoring system for artesunate treatment failure prediction in malaria patients.

IF 3.4 2区 医学 Q1 PARASITOLOGY
Dasom Kim, Da Hoon Lee, Yubin Song, Jung Sun Kim, Hye Sun Gwak
{"title":"Development of a clinical risk scoring system for artesunate treatment failure prediction in malaria patients.","authors":"Dasom Kim, Da Hoon Lee, Yubin Song, Jung Sun Kim, Hye Sun Gwak","doi":"10.1016/j.ijpddr.2025.100621","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe malaria remains a major cause of morbidity and mortality worldwide. Early identification of patients at high risk of poor response to treatment is essential, yet no simple clinical tool is currently available. This study aimed to develop a risk scoring system to predict failure to artesunate therapy.</p><p><strong>Methods: </strong>This retrospective study included adult patients (aged ≥18 years) who received at least one dose of intravenous artesunate at the National Medical Center in South Korea between 2014 and 2023. Treatment failure (early or late clinical failure) was the response variable, which was defined according to WHO criteria. Candidate predictor variables included demographic, clinical, parasitological, and laboratory parameters. Odds ratios (ORs) and adjusted odds ratios (aORs) were calculated using univariate and multivariable logistic regression analyses, respectively. Final predictors were selected through backward elimination based on the Likelihood Ratio criterion, and a clinical risk scoring system was developed based on the adjusted ORs.</p><p><strong>Results: </strong>Among 98 patients included in the final analysis, treatment failure occurred in 12 (12.2 %). Multivariable analysis identified female sex, parasitemia >5 %, and impaired consciousness as independent risk factors. Using these variables, a risk-scoring system was constructed, and the predicted probabilities of treatment failure for patients with scores of 0, 1, 2, 3, and 4 points were 5 %, 16 %, 41 %, 72 %, and 90 %, respectively (AUROC = 0.768, 95 % CI: 0.605-0.931).</p><p><strong>Conclusions: </strong>Parasitemia >5 %, impaired consciousness, and female sex were predictive of artesunate treatment failure as defined by WHO clinical criteria. The developed risk scoring system provides a practical tool for identifying high-risk patients requiring intensified monitoring and alternative treatment strategies. These findings are derived from a South Korean cohort and should be interpreted with caution when extrapolated to endemic populations.</p>","PeriodicalId":13775,"journal":{"name":"International Journal for Parasitology: Drugs and Drug Resistance","volume":"29 ","pages":"100621"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal for Parasitology: Drugs and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijpddr.2025.100621","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe malaria remains a major cause of morbidity and mortality worldwide. Early identification of patients at high risk of poor response to treatment is essential, yet no simple clinical tool is currently available. This study aimed to develop a risk scoring system to predict failure to artesunate therapy.

Methods: This retrospective study included adult patients (aged ≥18 years) who received at least one dose of intravenous artesunate at the National Medical Center in South Korea between 2014 and 2023. Treatment failure (early or late clinical failure) was the response variable, which was defined according to WHO criteria. Candidate predictor variables included demographic, clinical, parasitological, and laboratory parameters. Odds ratios (ORs) and adjusted odds ratios (aORs) were calculated using univariate and multivariable logistic regression analyses, respectively. Final predictors were selected through backward elimination based on the Likelihood Ratio criterion, and a clinical risk scoring system was developed based on the adjusted ORs.

Results: Among 98 patients included in the final analysis, treatment failure occurred in 12 (12.2 %). Multivariable analysis identified female sex, parasitemia >5 %, and impaired consciousness as independent risk factors. Using these variables, a risk-scoring system was constructed, and the predicted probabilities of treatment failure for patients with scores of 0, 1, 2, 3, and 4 points were 5 %, 16 %, 41 %, 72 %, and 90 %, respectively (AUROC = 0.768, 95 % CI: 0.605-0.931).

Conclusions: Parasitemia >5 %, impaired consciousness, and female sex were predictive of artesunate treatment failure as defined by WHO clinical criteria. The developed risk scoring system provides a practical tool for identifying high-risk patients requiring intensified monitoring and alternative treatment strategies. These findings are derived from a South Korean cohort and should be interpreted with caution when extrapolated to endemic populations.

用于疟疾患者青蒿琥酯治疗失败预测的临床风险评分系统的开发。
背景:严重疟疾仍然是全世界发病率和死亡率的主要原因。早期识别对治疗反应不良的高风险患者至关重要,但目前尚无简单的临床工具。本研究旨在建立一个风险评分系统来预测青蒿素治疗的失败。方法:这项回顾性研究纳入了2014年至2023年间在韩国国家医疗中心接受至少一剂静脉注射青蒿琥酯的成年患者(年龄≥18岁)。治疗失败(早期或晚期临床失败)是反应变量,根据世卫组织标准定义。候选预测变量包括人口统计学、临床、寄生虫学和实验室参数。分别使用单变量和多变量logistic回归分析计算优势比(ORs)和调整优势比(aORs)。根据似然比标准反向剔除最终预测因子,并根据调整后的or建立临床风险评分系统。结果:最终分析的98例患者中,12例(12.2%)出现治疗失败。多变量分析发现女性、寄生虫血症5%和意识受损是独立的危险因素。利用这些变量构建风险评分系统,0分、1分、2分、3分和4分患者治疗失败的预测概率分别为5%、16%、41%、72%和90% (AUROC = 0.768, 95% CI: 0.605-0.931)。结论:根据世卫组织临床标准,寄生虫血症5%、意识受损和女性是青蒿琥酯治疗失败的预测因素。开发的风险评分系统为识别需要加强监测和替代治疗策略的高危患者提供了实用工具。这些发现来自韩国的一个队列,在推断到流行人群时应谨慎解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
7.50%
发文量
31
审稿时长
48 days
期刊介绍: The International Journal for Parasitology – Drugs and Drug Resistance is one of a series of specialist, open access journals launched by the International Journal for Parasitology. It publishes the results of original research in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信